ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Entasis Therapeutics Holdings Inc

Entasis Therapeutics Holdings Inc (ETTX)

2.19
0.00
(0.00%)
Cerrado 23 Noviembre 3:00PM
0.00
0.00
(0.00%)
Fuera de horario: -

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Estadísticas y detalles clave

Último Precio
2.19
Postura de Compra
2.21
Postura de Venta
2.19
Volume Operado de la Acción
-
0.00 Rango del Día 0.00
0.00 Rango de 52 semanas 0.00
Precio Anterior
2.19
Precio de Apertura
-
Hora
Última hora de negociación
Volumen promedio (3 m)
-
Volumen financiero
-
Precio Promedio Ponderado
-

ETTX Últimas noticias

Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR to be Presented at IDWeek 2022

WALTHAM, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc., a late-stage clinical biopharmaceutical company focused on the discovery and development of novel...

Innoviva Announces Expiration of Cash Tender Offer for Shares of Entasis Therapeutics Holdings Inc.

Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Entasis Therapeutics Holdings Inc...

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Entasis Therapeutics Holdings Inc.

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Entasis Therapeutics Holdings Inc. PR Newswire NEW YORK, May 24, 2022 NEW YORK, May 24, 2022 /PRNewswire/ -- Rowley Law PLLC is...

Zai Lab and Entasis Therapeutics Announce Positive Topline Results for Sulbactam-Durlobactam (SUL-DUR) from Phase 3 ATTACK Trial

SUL-DUR first to achieve statistical non-inferiority in 28-day all-cause mortality in carbapenem-resistant Acinetobacter (CRAB) patients Statistically significant difference in clinical cure at...

Entasis Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

– ATTACK Phase 3 topline data readout remains on track for second half of 2021 –            – Strengthened balance sheet with $20M financing – WALTHAM, Mass., May 05, 2021 (GLOBE NEWSWIRE...

Entasis Therapeutics Completes Initial Closing of $20M Private Placement with Innoviva

WALTHAM, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...

Entasis Therapeutics Reports Full Year 2020 Financial Results and Provides Business Update

– Phase 3 ATTACK registration trial more than three-quarters complete –– ATTACK topline data readout expected second half of 2021 –– Zoliflodacin Phase 3 trial adds clinical trial sites, continues...

Entasis Therapeutics Announces Sulbactam-Durlobactam Expanded Access Program for Patients in the U.S.

WALTHAM, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...

Entasis Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference

WALTHAM, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...

Entasis Therapeutics to Participate in A.G.P.’s Virtual Healthcare Symposium

WALTHAM, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
PDYNPalladyne AI Corporation
US$ 4.59
(129.50%)
83.07M
QMCOQuantum Corporation
US$ 9.11
(126.62%)
39.48M
NANano Labs Ltd
US$ 8.26
(89.02%)
2.03M
XCURExicure Inc
US$ 18.60
(71.27%)
4.59M
SKKSKK Holdings Limited
US$ 1.75
(59.09%)
107.47M
AMIXAutonomix Medical Inc
US$ 6.21
(-54.07%)
946.09k
CETXCemtrex Inc
US$ 0.1146
(-41.74%)
24.39M
MSWMing Shing Group Holdings Ltd
 5.90
(-35.52%)
417.08k
RMSGReal Messenger Corporation
US$ 3.09
(-26.25%)
313.51k
ENSCEnsysce Biosciences Inc
US$ 0.4414
(-25.49%)
4M
ELABElevai Labs Inc
US$ 0.0201
(-0.50%)
425.38M
NVDANVIDIA Corporation
US$ 141.95
(-3.22%)
236.51M
SMCISuper Micro Computer Inc
US$ 33.15
(11.62%)
159.61M
VRPXVirpax Pharmaceuticals Inc
US$ 0.5501
(-6.72%)
159.39M
SOUNSoundHound AI Inc
US$ 8.24
(18.05%)
107.91M

ETTX Discussion

Ver más
Pedro2004 Pedro2004 3 años hace
Yes...keep an eye on this for a later date. Once they're finished with the selling, this should pop.
👍️0
swampboots swampboots 3 años hace
Ok that explains the $1 dollar fall from highs, last night.
👍️0
Pedro2004 Pedro2004 3 años hace
We have entered into an Controlled Equity Offering SM Sales Agreement (the “sales agreement”) with Cantor Fitzgerald & Co. (“Cantor”), dated as of August 27, 2021, relating to the offer and sale of shares of our common stock. In accordance with the terms of the sales agreement, under this prospectus supplement and the accompanying prospectus, we may offer and sell shares of our common stock having an aggregate offering price of up to $17,500,000 from time to time through Cantor acting as sales agent.
👍️0
swampboots swampboots 3 años hace
ETTX $+ data confirms, what is addressable market?
👍️0
frugalNorwegian frugalNorwegian 3 años hace
New reddit group talking only about ETTX.

https://reddit.com/r/ETTX_Stock
👍️0
BooDog BooDog 3 años hace
Very cool. I took my eyes off this one at the wrong time!

Nice!
👍️0
Snug Harbour Snug Harbour 3 años hace
Ya Baby!
👍️0
BooDog BooDog 4 años hace
2.73 high, who knew
👍️0
BooDog BooDog 4 años hace
Interesting looking charts. Something cooking here?
👍️0
BooDog BooDog 4 años hace
In 1.85 this morning pre market. See how this goes, BOD looks pretty solid.
👍️0
Sluicebox Sluicebox 4 años hace
Super odd, they're selling the stocks and warrants they bought in the September offer @2,67, so selling with a loss ?
The week before data ?
What do they know today that they didn't know back in September?
👍️0
dirtydozen911 dirtydozen911 4 años hace
doing a little digging...........the prospectus filed a few days ago is NOT the company selling shares....it is 2 of its largest holders JUMPING SHIP !!.......innoviva and armistice capital

they combined , are selling over 18 million shares, or about half the O S .....if the 35,475,441 is accurate.....i see why they tried to pump this early this morn.......i suspect massive selling today

DANGER...DANGER............GLA
👍️0
dirtydozen911 dirtydozen911 4 años hace
offering announced 3 days ago.....prob get hit with it at 4 p m ..gl
👍️0
Covid19freak Covid19freak 4 años hace
Great buying opportunity here close at ATL ,,,dirt cheap stock at $72 million valuation which has 2 phase 3 drugs with first readout expected next quarter . A potential 10 bagger and more here ..GL

Presentation October
https://investors.entasistx.com/static-files/0bf75506-2d54-4b14-896a-6a3d5ed53472

Major Shareholders

Innoviva Inc ...18.7M
Armistice ...3.5M
AstraZeneca PLC ...2.2M
Clarus Ventures, LLC ...1.3M
Pivotal ...1.2M
Sofinnova ...1.2M
Novo Holdings A/S ...1.2M
TPG Capital, L.P....1.0M
Eventide Asset ...879.5K
Frazier ...350.0K


👍️0
swingingRichard swingingRichard 4 años hace
This is awesome. Trusted the model and averaged down just twice.
👍️0
swingingRichard swingingRichard 4 años hace
$ETTX Sold too early. Made only %28. The model works!!!!

HOTD (so far was $4.25). Still, I'll take 28% any day of the week. So far this year, no losing plays using the model. Now, to be fair, I did have some losing trades, things I should have just left alone after making 150%.

* * * Chart Analysis * * *
👍️0
BioSpecialist BioSpecialist 4 años hace
Dirt cheap biotech gem

ETTX =MC $80 M / Cash $63 M / 2 MEGA Drugs with Phase 3 readouts in short term /Undiscovered low float stock
👍️0
BioSpecialist BioSpecialist 4 años hace
(ETTX-DD) Low Valuation of $86 Million / STRONG Cash of $63 Million/ 2 attractive Drugs in late Phase 3 with LARGE market potential with first readout within 6-7 months / Insider & Institutional investors holding most of the shares /Low float stock = $15-20 stock here on this undiscovered biotech gem .GL


Presentation June
https://investors.entasistx.com/static-files/0bf75506-2d54-4b14-896a-6a3d5ed53472

Major Shareholders

Innoviva Inc...14M
Novo Holdings A/S...2.2M
AstraZeneca PLC...2.2M
Clarus Ventures, LLC...1.6M
Pivotal ...1.2M
Sofinnova ...1.2M
Frazier ...1.0M
TPG Capital, L.P...1.0M
Eventide Asset ...879.5K
Granahan ...154.7K



👍️0
Wild Wild West Wild Wild West 4 años hace
Big move coming here IMO

Giddy up ETTX
👍️0

Su Consulta Reciente

Delayed Upgrade Clock